Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate Cancer
Andrew W. Hahn, MD, analyzes systemic therapy choices for men with metastatic hormone-sensitive prostate cancer. #urology #urologist #prostatecancer #oncology #metastatic #therapy
▶︎
Understanding Intermittent Hormone Therapy For #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
▶︎
Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate Cancer
▶︎
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
▶︎
Treatment of Oligometastatic Prostate Cancer: Systemic Therapy and Radiation to the Metastasis
▶︎
Don't Biopsy Your Prostate Until You Hear This (Part 2)
▶︎
Gleason Score 8 vs Lower Scores | What's The Real Difference?
▶︎
What is the ideal duration of hormone therapy for the treatment of prostate cancer?
▶︎
Prostate Cancer Cure Explained: PSA, Recurrence, and Survival
▶︎
Chemo, Hormone Therapy, and Radiation For Advanced Metastatic #ProstateCancer #MarkScholzMD #PCRI
▶︎
Optimal Duration of Hormone Therapy For #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI
▶︎
High-risk prostate cancer: what patients and physicians should know in 2026
▶︎
Your Prostate Needs More Than PSA
▶︎
The Power Of Exercise For Prostate Cancer | Robert Newton, PHD & Q+A with Mark Moyad, MD #PCRI
▶︎
Gleason 3+4 vs 4+3: Which One Is More Dangerous?
▶︎
Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET Imaging
▶︎
Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies
▶︎
Apalutamide, ADT Improve Outcomes in High-Risk Prostate Cancer Post-Surgery
▶︎
Avoiding Decision Regret in Prostate Cancer Treatment
▶︎
Is It Really Prostate Cancer? Rethinking Diagnosis, Biopsies, and the Gleason Score
▶︎